Giles Platford/LinkedIn
Dec 12, 2025, 09:34
Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, shared on LinkedIn:
”Plasma-derived therapies are often the only effective treatment for patients with certain rare and complex, chronic conditions.
One case in point is infant botulism: in partnership with the California Department of Public Health, on a non-profit basis, Takeda produces the only FDA-approved treatment for this condition, Baby Big.
The recent outbreak of infant botulism in the U.S. has put a fine point on the importance of this therapy.
Learn more in this story from The Independent”
Stay updated with Hemostasis Today.
-
Sep 25, 2026, 14:54James Fildes: Modeling Device Related Thrombosis in Multi Organ Systems
-
Sep 25, 2026, 14:51Platelet Metabolic Reprogramming: How Cellular Energy Drives Thrombosis
-
Sep 25, 2026, 14:46Thomas Maxwell: From Hemophilia Shame to Strength – Walking for Bleeding Disorders
-
Sep 25, 2026, 14:35Sarita Rani Jaiswal: Sharing Basic Science Insights at EBMT HWP 2026
-
Sep 25, 2026, 14:12Managing Breakthrough Bleeds in Hemophilia – National Bleeding Disorders Foundation
-
Sep 25, 2026, 13:50Alejandro González Veliz: Beyond the Golden Hour in Stroke Care
-
Sep 25, 2026, 13:32Gevorg Yaghjyan: Low Drug Levels, Higher Cardiovascular Risk in Lupus
-
Sep 25, 2026, 12:53Bastu Odoka: What Happened to Blood Donation?
-
Sep 25, 2026, 12:43Thomas Dayspring: Reshaping the Biology of Atherosclerotic Plaques with New Therapies